Baker & McKenzie LLP
04/30/2026 | Press release | Distributed by Public on 04/29/2026 22:23
Baker McKenzie Advises Abbisko on Rule 144A and Regulation S Share Placement
Baker McKenzie has advised Abbisko Cayman Limited (Abbisko), a leading Hong Kong listed biopharmaceutical company, in raising approximately HKD 522 million through the Rule 144A and Regulation S placement of new shares.
Abbisko is a clinical stage biopharmaceutical company committed to the research, discovery, and development of innovative and differentiated medicines designed to address unmet medical needs in China and globally. The net proceeds will be used for the research and development of innovative oncology and non-oncology drug candidates, the advancement of international multi-centre clinical trials, and potential commercialization activities as well as for general and corporate use. Please refer to the company's announcement for further details about the deal.
The deal team was led by Sheng Chen^, Partner of Baker McKenzie and Yolanda Zheng, Partner at FenXun Partners*. They were supported by Senior Associates Phoebe Wang, Xiaoyang Hu and Vicky Zheng, and Vicky Ding across Shanghai and Hong Kong offices.
Commenting on the deal, Sheng Chen said: "We are pleased to have supported Abbisko on this important financing. The transaction reflects strong investor confidence in the company's scientific capabilities and growth prospects, and underscores Hong Kong's position as an effective capital raising platform for innovative biopharmaceutical companies."
Yolanda added: "Our involvement in this transaction highlights the breadth and depth of our capital markets capabilities and our ability to combine the strength of Baker McKenzie and FenXun to offer seamless cross-border law advice that our clients highly value."
Baker McKenzie is one of the leading firms for complex transactions, providing strategic advice on deals involving the world's leading financial institutions and multinational companies. The Firm regularly advises target companies, offerors, selling shareholders and financial advisers on the acquisition and disposal of companies listed on stock exchanges in key major financial centers, as well as issuers on their proposed listing and fundraising activities in different jurisdictions. With many of its lawyers enjoying established working relationships with local regulators in Hong Kong and other key markets, the Firm is well-positioned to guide clients through every stage of the process - providing valuable insights on regulatory developments that may affect the value and feasibility of cross-border transactions, as well as on ongoing compliance matters. The team also assists listed companies in the restructuring of shareholdings, the use of stock as consideration, and the execution of block trades. Moreover, the team has extensive experience in advising clients on cross-border capital fundraising through various schemes, including the Shanghai-London Stock Connect and the China-Switzerland Stock Connect.
^ Registered Foreign Lawyer
*Baker McKenzie established a joint operation office with FenXun in China as Baker McKenzie FenXun, approved by the Shanghai Justice Bureau in 2015.
Abbisko is a clinical stage biopharmaceutical company committed to the research, discovery, and development of innovative and differentiated medicines designed to address unmet medical needs in China and globally. The net proceeds will be used for the research and development of innovative oncology and non-oncology drug candidates, the advancement of international multi-centre clinical trials, and potential commercialization activities as well as for general and corporate use. Please refer to the company's announcement for further details about the deal.
The deal team was led by Sheng Chen^, Partner of Baker McKenzie and Yolanda Zheng, Partner at FenXun Partners*. They were supported by Senior Associates Phoebe Wang, Xiaoyang Hu and Vicky Zheng, and Vicky Ding across Shanghai and Hong Kong offices.
Commenting on the deal, Sheng Chen said: "We are pleased to have supported Abbisko on this important financing. The transaction reflects strong investor confidence in the company's scientific capabilities and growth prospects, and underscores Hong Kong's position as an effective capital raising platform for innovative biopharmaceutical companies."
Yolanda added: "Our involvement in this transaction highlights the breadth and depth of our capital markets capabilities and our ability to combine the strength of Baker McKenzie and FenXun to offer seamless cross-border law advice that our clients highly value."
Baker McKenzie is one of the leading firms for complex transactions, providing strategic advice on deals involving the world's leading financial institutions and multinational companies. The Firm regularly advises target companies, offerors, selling shareholders and financial advisers on the acquisition and disposal of companies listed on stock exchanges in key major financial centers, as well as issuers on their proposed listing and fundraising activities in different jurisdictions. With many of its lawyers enjoying established working relationships with local regulators in Hong Kong and other key markets, the Firm is well-positioned to guide clients through every stage of the process - providing valuable insights on regulatory developments that may affect the value and feasibility of cross-border transactions, as well as on ongoing compliance matters. The team also assists listed companies in the restructuring of shareholdings, the use of stock as consideration, and the execution of block trades. Moreover, the team has extensive experience in advising clients on cross-border capital fundraising through various schemes, including the Shanghai-London Stock Connect and the China-Switzerland Stock Connect.
^ Registered Foreign Lawyer
*Baker McKenzie established a joint operation office with FenXun in China as Baker McKenzie FenXun, approved by the Shanghai Justice Bureau in 2015.
Baker & McKenzie LLP published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 30, 2026 at 04:23 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]